Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its twelfth fund, at $400m.
Atlas Venture will continue to focus on building biotech companies to deliver high-impact therapies to patients.
With the closing of Fund XII, Michael Gladstone was promoted to partner.
Gladstone joined Atlas in 2012 and has been a key contributor to many portfolio companies over the last eight years, including Akero, AVROBIO, Delinia, IFM, and others.
Alongside Gladstone, the six investing partners in Fund XII also include Jason Rhodes, Bruce Booth, Kevin Bitterman, Jean-FranÃ§ois Formela, and David Grayzel.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Startup founders are leaving the Silicon Valley “bubble” and heading to the East coast.
Search Startup Around
Boost Your Discovery with Us
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.